Panobacumab is under clinical development by Aridis Pharmaceuticals and currently in Phase II for Pseudomonas aeruginosa Pneumonia. According to GlobalData, Phase II drugs for Pseudomonas aeruginosa Pneumonia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Panobacumab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Panobacumab overview
AR-101 (panobacumab, KBPA101) is under development for the treatment of Pseudomonas aeruginosa pneumonia in ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) infection. The drug candidate is administered as an intravenous infusion in the form of the solution. KBPA101 is a human monoclonal antibody of the immunoglobulin M isotype, which is directed against the O-polysaccharide moiety of Pseudomonas aeruginosa serotype. It is based on the MabIgX technology.
Aridis Pharmaceuticals overview
Aridis Pharmaceuticals (Aridis) is a biopharmaceutical company. The company’s pipeline products include AR-301 (tosatoxumab), AR-320 (suvratoxumab), AR-501 (Gallium Citrate), AR-701 (COVID-19 mAb). AR-301 (tosatoxumab) is a Human anti-S. aureus mAb for therapeutic treatment of VAP, AR-320 (suvratoxumab) is a Long-acting human anti-S. aureus for prevention of VAP, AR-501 (Gallium Citrate) is a novel anti-infective for the growing problem of antibiotic resistance, AR-701 (COVID-19 mAb) Human mAb Cocktail to SARS-CoV-2 Virus. The company also works on macromolecular stabilization technology for increase the stability of vaccines. Aridis is headquartered in San Jose, California, the US.
For a complete picture of Panobacumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
